The Gravitate-Health mission is to bring innovative digital health information tools to patients and empower person-centred healthcare.
About the project
Gravitate-Health is an integrated digital health information project.
It is a public – private partnership with 39 members in 15 countries, co-lead by University of Oslo (public partner coordinator) and Pfizer (private industry lead).
We believe engaging citizens in their own health relies on actionable, understandable, relevant, reliable and evidence-based information that meets their specific needs, health context, and literacy level.
Gravitate-Health aims for improved access and understanding of health information, for safe use of medicines, risk minimization and improved quality of life.
"Empowering and Equipping Europeans
with Health Information for Active, Personal Health Management and Adherence to Treatment."
Digital technology offers novel opportunities to personalize medicinal product information.
Currently, patients primarily receive this information in the form of a paper leaflet provided with their medicine. This presents a range of practical challenges to access and understanding.These problems are likely to be aggravated by aging, multimorbidity and chronic diseases, with many patients needing to refer to multiple paper leaflets for different medicines.
Making regulator-approved medicinal product information from a trusted authorized source digitally available to patients and healthcare professionals is fundamental to support the digital transformation of healthcare across the EU.
Gravitate-Health will develop and test an integrated, digital, user-centric health information solution seeking to demonstrate tangible improvements in availability and understanding of health information from a set of trusted sources, starting with regulator-approved medicinal product information and the Electronic Health Record International Patient Summary (EHR-IPS).
The Action seeks to demonstrate that such improvement translates to higher levels of adherence to treatment, safer use of medication (Pharmacovigilance), and better health outcomes and quality of life.
Safe use of medication and adherence to treatment are significant public health challenges where understanding, access to accurate information, capabilities to comprehend, and trust play major roles.
OECD estimates that around 200,000 premature deaths annually in Europe relate to poor medication adherence, which may cost as much as €125 billion each year in avoidable hospitalization, emergency care and adult outpatient visit.
Empirical studies of information flows in health care show lack of interoperability and broken chains of activity which complicate information sharing. Medication information can be fragmented, unavailable or not used, so introducing risks of which the user may be unaware, for example risk of errors in use that can lead to adverse events, disability, and even death.
The project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 945334. This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations [EFPIA]. The total budget is 18.5M€ for a project duration of 60 months.
Public – private partnership with 39 members from 15 countries from Europe and the US.
Start and Finish
November 2020 - November 2025